Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03184870 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 332
- Enrollment target
NCT03184870: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03184870 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 332 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (453% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03184870, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
Primary Outcome
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately lif
Interventions
- DRUG Gemcitabine
- BIOLOGICAL Nivolumab
- DRUG Nab-paclitaxel
- DRUG 5-fluorouracil (5-FU)
- DRUG BMS-813160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 1 |
What the finished NCT03184870 record still lists
NCT03184870 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (453% higher).
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT03184870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03184870 about?
NCT03184870 is a clinical study titled "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
What is the current status of trial NCT03184870?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 332 participants. The study started on 2017-08-08. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT03184870?
The interventions under investigation include: Gemcitabine (DRUG), Nivolumab (BIOLOGICAL), Nab-paclitaxel (DRUG), 5-fluorouracil (5-FU) (DRUG), BMS-813160 (DRUG).
Who is sponsoring clinical trial NCT03184870?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03184870's enrollment target sits among peer trials
332 108th of 2000 higher than 1,891 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI